SOUTHAMPTON, United Kingdom, January 6, 2022 / PRNewswire / – Synairgen plc (LSE: SNG), the respiratory company developing SNG001 (inhaled beta interferon or IFN-beta) for the treatment of COVID-19 as potentially the first broad-spectrum antiviral therapy targeted at host delivered directly to the lungs, today announced a partnership with Ashfield Engage, a global expert in strategic engagement and commercialization.

Leveraging its COVID-19 experience, Ashfield Engage is supporting Synairgen in building its commercialization infrastructure for the needs of SNG001, initially in the United States, pending completion of pivotal trials and regulatory approvals. This will include recruiting dedicated medical affairs, patient services, sales and market access teams.

SNG001 is an experimental inhaled formulation of the natural IFN-beta antiviral protein for potential use in hospital patients with COVID-19. The SARS-CoV-2 virus suppresses the local production of IFN-beta and prevents the induction of antiviral responses by infected cells.

“There remains an urgent need for new therapies to treat hospitalized COVID-19 patients to prevent the progression of the disease, speed up discharge from hospital and allow patients to quickly return to their usual activities. ” noted Richard hennings, Sales Director of Synairgen. “We are excited to be working with Ashfield Engage given their relevant COVID-19 experience and are confident that they understand our needs and values ​​as we build the optimal team. ”

In November 2021, Synairgen announced that it has completed the enrollment of 610 patients in its Phase 3 SPRINTER trial (SG018) and expects first-rate data early this year. SNG001 also recently moved to Phase 3 of the US National Institute of Health’s ACTIV-2 trial.

Greg flynn, Global President of Ashfield Engage, said: “It is a privilege to support Synairgen in bringing this potential innovative treatment to COVID-19 patients. providing solutions both in hospital and at home.

“We are grateful that our collaboration has now evolved into a much larger partnership which will allow us to recruit experts to support the delivery of this new nebulized antiviral to patients, to provide MSL to inform about the SNG001 treatment and to establish medical information services to respond to patient inquiries. “

SNG001 has obtained Fast Track status from the United States Food and Drug Administration (FDA) and the phase 3 trial SPRINTER has been classified as an urgent public health study by the United Kingdom National Institute for Health Research. Uni (NIHR).

No financial terms were disclosed regarding the partnership with Ashfield Engage.

For more information, please contact:

Synairgen plc
Richard marsden, Chief executive officer
John ward, Financial director
Brooke clarke, responsible for the communication
[email protected]
Phone: + 44 (0) 23 8051 2800

finnCap (NOMAD and Joint Broker)
Geoff nash, Kate bannatyne, Charlie beeson (Business Finance)
Alice lane, Sunil de Silva (GUY)
Phone: + 44 (0) 20 7220 0500

Numis Securities Limited (Co-broker)
James black, Freddie barnfield, Duncan Monteith
Phone: + 44 (0) 20 7260 1000

Consilium Strategic Communications (Financial Media and Investor Relations)
Mary-Jane Elliott, Jessica hodgson, Lucy featherstone
[email protected]
Phone: +44 (0) 20 3709 5700

MKC STRATEGIES, LLC (US Media Relations)
Marie conway
[email protected]
Phone. : +1 516-606-6545

Notes for Editors

About Synairgen
Synairgen is a UK-based respiratory company focused on drug discovery, development and commercialization. The Company’s primary goal is to develop SNG001 (inhaled beta interferon) for the treatment of COVID-19 as potentially the first broad-spectrum host-targeted antiviral therapy delivered directly to the lungs. SNG001 has obtained Fast Track status from the United States Food and Drug Administration (FDA) and the phase 3 trial SPRINTER has been considered an urgent public health study by the United Kingdom National Institute for Health Research. Uni (NIHR). Synairgen’s Phase 3 clinical program is currently evaluating SNG001 in patients in 17 countries. In a phase 2 trial in hospitalized COVID-19 patients, SNG001 demonstrated a more than twice the chance of recovery at “no activity limitation” compared to placebo.¹

Founded by the professors of the University of Southampton, Sir Stephen holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen was listed on AIM (LSE: SNG). For more information on Synairgen, please see www.synairgen.com.

¹https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30511-7/fulltext

About Ashfield Engage

Ashfield Engage is an expert global partner in client strategy and execution. Ashfield Engage helps clients connect with all healthcare audiences to ensure people get knowledge, support, and medication when and where they need it. As an expert in strategic engagement, Ashfield Engage creates personalized and impactful experiences for all healthcare audiences, across all channels. Each program is underpinned by people connections, omnichannel engagement, and adaptive analytics.

Ashfield Engage has over 20 years of experience with a team of over 5,000 employees, providing services in over 50 countries. Offering services in medical business, business, patient solutions and event experiences, Ashfield Engage helps clients engage with their stakeholders throughout the journey to market.

For more information visit www.ashfieldengage.com

SOURCE Synairgen PLC